Skip to Main Content

Paper Details

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Mod Pathol
53
2021
ATM, ATM-altered prostate cancer, BRCA1/2, BRCA2, BRCA2 mutations, BRCA2-, CHEK2, HR gene, HRD, Homologous recombination deficiency, PARP, PROGENE, TCGA, TP53, TP53 mutations, germline, homologous recombination deficiency, olaparib, ovarian carcinoma, patients, primary prostate cancer, prostate cancer, prostate cancers, telomeric, tumors
Author NameAffiliation
Tamara L LotanJohns Hopkins School of Medicine
Tamara L LotanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Tamara L LotanJohns Hopkins University School of Medicine
Edward M SchaefferNorthwestern University
William B IsaacsJohns Hopkins University School of Medicine
Robert BrownDivision of Cancer and Ovarian Cancer Action Research Centre, Imperial College London
Andrea L RichardsonJohns Hopkins School of Medicine
Emmanuel S AntonarakisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Emmanuel S AntonarakisJohns Hopkins University School of Medicine
  • 1 - 9

Datasets

Release 1.2